FDA APPROVES SCHERING-PLOUGH'S CLARINEX 12-HOUR

Schering-Plough has received FDA approval for its allergy drug Clarinex 12-hour extended-release tablets. The company plans to market Clarinex 12-hour (desloratadine 2.5 mg and pseudoephedrine sulfate, USP 120 mg) starting in March. The product is indicated for the relief of nasal and non-nasal symptoms of seasonal outdoor allergies, including nasal congestion, in patients 12 years of age and older.